Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jörgen Johnsson is active.

Publication


Featured researches published by Jörgen Johnsson.


Archives of Dermatological Research | 2005

Pentane-1,5-diol as a percutaneous absorption enhancer

Jan Faergemann; Björn Wahlstrand; Thomas Hedner; Jörgen Johnsson; Reinhard H.H. Neubert; Lena Nyström; Howard I. Maibach

Propylene glycol (propane-1,2-diol) is the only diol widely used in dermatology. Pentane-1,5-diol is mainly used as a plasticizer in cellulose products and adhesives, in dental composites and in brake fluid compositions and as a preservative for grain. However, pentane-1,5-diol is also an effective solvent, water-binding substance, antimicrobial agent and preservative and may therefore replace several ingredients in a skin composition. The release of tri-iodothyroacetic acid (TRIAC) and percutaneous absorption of hydrocortisone and mometasone furoate with either pentane-1,5-diol or propane-1,2-diol and 2-methyl-pentane-2,4-diol (hexylene glycol), respectively, as enhancers was compared. The release of TRIAC was 21% higher when pentane-1,5-diol was used as an enhancer instead of propane-1,2-diol. The percutaneous absorption of hydrocortisone through the skin was increased 12 times with propane-1,2-diol compared to 4.4 times with pentane-1,5-diol. However, the percutaneous absorption of hydrocortisone into the skin was 50% higher with pentane-1,5-diol compared to propane-1,2-diol. There was no significant difference, between the original mometasone furoate cream, with 2-methyl-pentane-2,4-diol, and the new cream with pentane-1,5-diol in the amount of mometasone furoate that was absorbed into the skin and through the skin. However, the cosmetic properties of the new mometasone furoate cream was superior to the original mometasone furoate cream, for examples, no bad odour, more even texture, goes better into the skin and has less greasiness. Pentane-1,5-diol can be used as a technology platform, which adds a series of desirable properties to dermatological preparations and enhances product usability. This will result in improved formulations for a series of major and commonly used dermatological drugs. When used in pharmaceutical topical preparations, pentane-1,5-diol will increase the percutaneous absorption of the active substance and it is an efficient antimicrobial agent that will act as an effective preservative in topical formulations. Pentane-1,5-diol is cosmetically attractive, has low risk for skin and eye irritation compared to other diols, low toxicity risk and no bad odour.


Archive | 2005

Pharmaceutical compositions for acute glucocorticoid therapy

Stanko Skrtic; Jörgen Johnsson; Hans Lennernäs; Thomas Hedner; Gudmundur Johannsson


Archive | 2005

Pharmaceutical compositions for glucocorticoid replacement therapy

Stanko Skrtic; Jörgen Johnsson; Hans Lennernäs; Thomas Hedner; Gudmundur Johannsson


Archive | 2010

Improved glucocorticoid therapy

Hans Lennernäs; Jörgen Johnsson; Thomas Hedner; Gudmundur Johannsson; Stanko Skrtic


Archive | 2008

Use of fibrinogen as a prophylactic treatment to prevent bleeding during and after surgery and as a biomarker to identify patient with an increased risk for excessive bleeding and blood transfusion

Anders Jeppsson; Stanko Skrtic; Lennart Bruce; Jörgen Johnsson; Thomas Hedner


Archive | 2008

Use of oligomers of lactic acid in the treatment of gynaecological infections

Greg Batcheller; Thomas Hedner; Jörgen Johnsson; Werner Schubert; Christer Sjögren; Olov Sterner; Malgorzat Sznitowska


Archive | 2017

TREATMENT OF SKIN ATROPHY WITH A COMBINATION OF TRIIODOTHYROACETIC ACID (TRIAC) AND DEHYDROEPIANDROSTERONE (DHEA)

Jan Faergemann; Gudmundur Johannsson; Claes Ohlsson; Derek Gregory Batcheller; Jörgen Johnsson; Jan Törnell


Archive | 2013

Use of oligomer of lactic acid in treatment of gynecological disorder

Greg Batcheller; バッチェラー,グレッグ; Hedner Thomas; ヘドナー,トーマス; Jörgen Johnsson; ジョンソン,ヨルゲン; Werner Schubert; シューバー,ワーナー; Sjoegren Christer; シェーグレン,クリスター; Olov Sterner; スターナー,オロヴ; Malgorzat Sznitowska; ズニトウスカ,マルゴーザット


Archive | 2010

Verbesserte glucokortikoid-therapie

Hans Lennernäs; Jörgen Johnsson; Thomas Hedner; Gudmundur Johannsson; Stanko Skrtic


Archive | 2008

Verwendung von fibrinogen als prophylaktische behandlung zur verhinderung von blutungen während und nach einer operation und als biomarker zur identifizierung von patienten mit erhöhten risiko für übermässige blutungen und bluttransfusion

Anders Jeppsson; Stanko Skrtic; Lennart Bruce; Jörgen Johnsson; Thomas Hedner

Collaboration


Dive into the Jörgen Johnsson's collaboration.

Top Co-Authors

Avatar

Thomas Hedner

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Werner Schubert

Sahlgrenska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jan Faergemann

Sahlgrenska University Hospital

View shared research outputs
Top Co-Authors

Avatar

Björn Wahlstrand

Sahlgrenska University Hospital

View shared research outputs
Top Co-Authors

Avatar

Claes Ohlsson

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge